MyBioSource

antibody

Human Insulin Monoclonal Antibody

MBS190240

0.2 mg

340 USD

monoclonal

mouse

human

ELISA, immunohistochemistry

MBS190240

Antibody

Human Insulin Monoclonal Antibody

Insulin

Anti-Insulin; Insulin

insulin; Insulin; insulin; proinsulin; OTTHUMP00000011161; OTTHUMP00000011162; OTTHUMP00000196036; OTTHUMP00000196038; OTTHUMP00000217519; insulin; N/A

INS; INS; ILPR; IRDN; IDDM2; MODY10; N/A

INS_HUMAN

Monoclonal

IgG1

Mouse

110

Anti-Insulin [Murine MAbs recognize human insulin; 20801 cross-reacts with bovine and porcine insulin (3 clones).]. All three antibodies recognize human insulin and cross-react with human proinsulin, bovine insulin, and porcine insulin. This product (C7C9) reacts with C-terminal pentapeptide of insulin beta chain; Kd = 10^-9 M.

200 ug Protein A-purified antibody in PBS, pH 7.4.

These antibodies are stable for at least one (1) year at -20 degree C to -70 degree C. Store product in appropriate aliquots to avoid multiple freeze-thaw cycles.

ELISA, Immunoassay, Immunohistochemistry

These antibodies may be used in immunoassays to detect and quantitate human insulin. 20802 and 20803 may be used as an antibody pair in a two-site ELISA. 20802 may be used in immunohistochemistry on frozen sections. Not all applications have been investigated.

Antigen: Purified human insulin.

Stabilizer: None. Preservatives: 0.1% sodium azide. Dilutions Instructions: Dilute in PBS or medium which is identical to that used in the assay system.

Hormone and Serum Protein Antibodies

386828

AAA59172.1

P01308

11,981 Da

ATF-2 Transcription Factor Network Pathway 138006!!Adipogenesis Pathway 198832!!Aldosterone-regulated Sodium Reabsorption Pathway 130626!!Aldosterone-regulated Sodium Reabsorption Pathway 130590!!Amyloids Pathway 366238!!Arf6 Trafficking Events Pathway 137954!!Diabetes Pathways 105902!!Downstream Signaling Of Activated FGFR Pathway 160957!!FOXA1 Transcription Factor Network Pathway 137979!!FOXA2 And FOXA3 Transcription Factor Networks Pathway 137911

After removal of the precursor signal peptide, proinsulin is post-translationally cleaved into three peptides: the B chain and A chain peptides, which are covalently linked via two disulfide bonds to form insulin, and C-peptide. Binding of insulin to the insulin receptor (INSR) stimulates glucose uptake. A multitude of mutant alleles with phenotypic effects have been identified. There is a read-through gene, INS-IGF2, which overlaps with this gene at the 5' region and with the IGF2 gene at the 3' region. Alternative splicing results in multiple transcript variants. [provided by RefSeq]

Function: Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver. Subunit structure: Heterodimer of a B chain and an A chain linked by two disulfide bonds. Subcellular location: Secreted. Involvement in disease: Defects in INS are the cause of familial hyperproinsulinemia (FHPRI) [. MIM:176730]. Ref.21 Ref.23 Ref.24 Ref.25Defects in INS are a cause of diabetes mellitus insulin-dependent type 2 (IDDM2) [. MIM:125852]. IDDM2 is a multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. Ref.34Defects in INS are a cause of diabetes mellitus permanent neonatal (PNDM) [. MIM:606176]. PNDM is a rare form of diabetes distinct from childhood-onset autoimmune diabetes mellitus type 1. It is characterized by insulin-requiring hyperglycemia that is diagnosed within the first months of life. Permanent neonatal diabetes requires lifelong therapy. Ref.32 Ref.33Defects in INS are a cause of maturity-onset diabetes of the young type 10 (MODY10) [. MIM:613370]. MODY10 is a form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease. Ref.33 Ref.34 Ref.35. Pharmaceutical use: Available under the names Humulin or Humalog (Eli Lilly) and Novolin (Novo Nordisk). Used in the treatment of diabetes. Humalog is an insulin analog with 52-Lys-Pro-53 instead of 52-Pro-Lys-53. Sequence similarities: Belongs to the insulin family. Sequence caution: The sequence AAA59179.1 differs from that shown. Reason: Erroneous gene model prediction.

0.2 mg

340 USD